Clinical Trial Update: A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) [Phase 3]

View source ↗

Summary

This clinical trial update notes that the long-term Phase 3 study of nemolizumab (CD14152) for prurigo nodularis is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prurigo Nodularis

Drugs mentioned

• Nemolizumab (nemolizumab)

Snippet

Sponsor: Galderma R&D | Conditions: Prurigo Nodularis | Phase 3 | Status: ACTIVE_NOT_RECRUITING